DrugDevCovid19

Tracking the relevant researches of CADD drug development against COVID-19

Loprazolam

ID MW HBD HBA
3033860  464.903
RB NOA Rings logP
2952.93

Function

DrugBank ID:

DB13643


Description:

Loprazolam is an imidazobenzodiazepine with anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings. Loprazolam is recommended as a short-term therapy only, due to adverse events associated with the drug including dependence and withdrawal symptoms. It is a positive modulator of GABA-A receptor that enhances the inhibitory neurotransmission. It is not an FDA-approved drug. [DrugBank]

Targets:

GABA(A) Receptor (Humans); GABA(A) Receptor Benzodiazepine Binding Site (Humans) [DrugBank]

Pharmacodynamics:

Not Available [DrugBank]

Structures

SMILES:

CN1CCN(/C=C2\N=C3CN=C(c4ccccc4Cl)c4cc([N+](=O)[O-])ccc4N3C2=O)CC1

2D structures:  

3D structures:  

Docking in target protein

Receptor: TMPRSS2

Docking Site: Catalytic pocket

Ligand: Loprazolam

Vina score: -7.7

Off-target analysis based on ligand similarity (Homo sapiens)

Step 1 - Target prediction for Loprazolam: SwissTargetPrediction

Tips: Click on the link to jump to the 'SwissTargetPrediction' webserver. Select the species of 'Homo sapiens', and then paste the SMILES of Loprazolam in the SMILES input box.

Step 2 - Blind docking for Loprazolam: CB-Dock

Tips: Click on the link to jump to the 'CB-Dock' webserver. Upload the structure file of target predicted by 'SwissTargetPrediction' and the 2D/3D structure file of Loprazolam to perform blind docking.